

Steering Committee, Participating Site Investigators, and Observational Study Monitoring Board

Steering Committee: Colleen R. Kelly (Co-Chair), Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI; Loren Laine (Co-Chair), Yale School of Medicine, New Haven, CT and Veterans Affairs Connecticut Healthcare System, West Haven, CT; Gary D. Wu, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Stacy Kahn, MD, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA; Thomas Moore, MD, Infectious Disease Consultants, KS; David Rubin, MD, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medicine, Chicago, IL; James Lewis, MD, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Ashish Atreja, MD, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY.

Participating Site Investigators: Eugene F. Yen, North-Shore University HealthSystem, Evanston, IL; Ari M. Grinspan, Icahn School of Medicine at Mount Sinai, New York, NY; Stacy A. Kahn, Boston Children's Hospital, Boston, MA; Jessica R. Allegretti, Brigham and Women's Hospital, Boston,

MA; Joel Pekow, University of Chicago Medicine, Chicago, IL; Imad Absah, Mayo Clinic, Rochester, MN; Ronald Hsu, University of California, Davis, CA; Jennifer Vincent, Baylor Scott and White Research Institute, Temple, TX; Sahil Khanna, Mayo Clinic, Rochester, MN; Lyn Tangen,¹⁹Carle Foundation Hospital, Urbana, IL; Carl V. Crawford, Weill Cornell Medicine, New York, NY; Mark C. Mattar, MedStar Georgetown University Hospital, Washington, DC; Lea Ann Chen, New York University Grossman School of Medicine, New York, NY; Monika Fischer, Indiana University, Indianapolis, IN; Razvan I. Arsenescu, Atlantic Digestive Health Institute, Morristown, NJ; Paul Feuerstadt, Medical Research Center of Connecticut, Hamden, CT; Jonathan Goldstein, Gastroenterology Group of Rochester, Rochester, NY; David Kerman, University of Miami, Miami, FL; Adam Ehrlich, Lewis Katz School of Medicine at Temple University, Philadelphia, Philadelphia, PA.

Observational Study Monitoring Board: Christina Surawicz (Chair), Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Erik R. Dubberke, Department of Medicine, Division of Infectious Diseases, School of Medicine, Washington University, St. Louis, MO; Allison C. Brown, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.

Supplementary Table 1. Data Elements at Baseline: Fecal Microbiota Transplantation Technique and Characteristics and Treatment Indications

Data element
FMT technique
Transplant material
Directed donor stool
Stool bank
Modified human stool
Cultured bacterial product derived from stool
Microbial consortia not derived from stool
Donor screening
Screening questionnaire
Interview
Physical examination
Serologic screening
Stool screening
Recipient screening
Baseline laboratory tests
Transplant material preparation
Location of preparation
Volume/weight of stool used
Diluents
Processing/filtration methods
Material storage
Capsule
Amount of material delivered (mL or g)
Method of delivery
Oral ingestion (capsules or liquid)
Nasogastric/intestinal tube
Endoscopic (upper or lower)
Enema
Other
Delivery schedule
Single dose
Multiple dose
Maintenance
Characteristic
Donor baseline
Demographics
Medical conditions
Recipient baseline
Demographics
Body mass index
Medical conditions
Laboratory data
CDI: strain, duration, pre-FMT treatments, severity of CDI, no. of episodes
IBD: type, duration, location severity, pre-FMT treatments, IBD history
FMT indication
CDI
CDI + IBD
IBD
Irritable bowel syndrome
Chronic constipation
Obesity
Diabetes
Metabolic syndrome
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Neurologic or neurodevelopmental disorder
Other

Supplementary Table 2.Data Elements: Effectiveness and Safety Outcomes

Data element
FMT effectiveness
CDI
Cure
Recurrence
Post-FMT CDI therapies
IBD
IBD-severity at times points post-FMT
IBD-related hospitalization post-FMT
IBD-related surgery post-FMT
IBD-related medications post-FMT
Complications
Safety outcomes collected at 1 month post FMT
Procedure-related
Sedation complications
Bleeding
Perforation
Other
Post-FMT symptoms
Diarrhea
Constipation
Abdominal pain
Bloating
Nausea and/or vomiting
Other
Documented infections
Describe
Relationship to FMT
Specify site
Hospitalization
Reason
Relationship to FMT
Duration
Outcome
Life-threatening experience
Describe
Relationship to FMT
Outcome
Death
Cause of death
Relationship to FMT
Site of death
Outcomes collected \geq 6 mo post FMT
Serious infection
Describe
Treatment
Duration of treatment
Outcome
Hospitalization
Use of new drugs
Describe
Currently taking?
New surgery/procedure
Describe
Diagnosis of new conditions
Allergy
Asthma
Autoimmune
Cardiovascular
Colon cancer and other malignancies
IBD

Supplementary Table 2.Continued

Data element
Irritable bowel syndrome
Metabolic
Neurologic
Psychiatric
Other
Hospitalization
Reason
Life-threatening illness
Describe
Outcome
Death
Cause of death
Site of death